Seroprevalence of hepatitis B virus, hepatitis C virus, and human immunodeficiency virus infections in patients with hereditary hemoglobinopathies from Saudi

Noomani, Nabil M.G. Al; Mahmoud, Nahed; Khalil, Shamsun Nahar A.T.M.

doi:10.1097/01.elx.0000403169.58285.4f

Cited by 2 publications

(2 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In Jordan, HCV prevalence was 40.5% [ 13 ], whereas in Lebanon, 14% of patients were positive for HCV [ 25 ]. In Saudi Arabia, a prevalence of 26% was reported in 2002 [ 30 ], while in 2011, 1.1% of multitransfused children had hepatitis B surface antigen, 3.5% were anti-HCV-positive, and none were anti-HIV-positive [ 31 ]. The current and future burden of diseases caused by viral hepatitis in Egypt is significant.…”

Section: Discussionmentioning

confidence: 99%

Transfusion Transmitted Hepatitis: Where Do We Stand Now? A One Center Study in Upper Egypt

El-Faramawy¹,

El-Rashidy

Tawfik

et al. 2012

Hepat Mon

View full text Add to dashboard Cite

BackgroundDespite progress made in the prevention of transfusion-transmitted infections (TTI) over the last few years, they continue to be a problem in many parts of the world, particularly in multitransfused patients.ObjectivesThe aim of this study was to estimate the prevalence of hepatitis B virus (HBV), hepatitis C virus (HCV), and to evaluate the screening and vaccination program among our cohort of multitransfused children from Qena, Upper Egypt.Patients and MethodsOne-hundred children suffering from diseases requiring repeated blood transfusions were included in the study. They were classified into group 1, which included 67 children with thalassemia, and group 2, which included 33 children with hemophilia. Screening for hepatitis B surface antigen, hepatitis B surface antibody, hepatitis B core antibody and antibody to HCV was done using a second-generation enzyme-linked immunosorbent assay technique.ResultsOnly 12% of all patients were either acutely or chronically infected with HBV. 46% were immune due to previous vaccination, whereas 39% of patients were not protected from HBV infection. HCV antibodies were positive in 45% of cases. Seventy-eight patients had a complete hepatitis B vaccination in the form of three doses as documented by birth certificate. Thirty-six patients mentioned history suggestive of hepatitis. The prevalence of the studied hepatitis markers was similar in both the thalassemia and hemophilia groups of children.ConclusionsTransfusion-transmitted hepatitis is still a major problem for multitransfused children in Egypt. More effort is required to reduce the infection rate through proper screening of blood and blood products, strict emphasis on receiving the vaccine, regular follow-up for those children with a hepatitis B antibody titer, and providing booster doses for those in need.

show abstract

Section: Discussionmentioning

confidence: 99%

Transfusion Transmitted Hepatitis: Where Do We Stand Now? A One Center Study in Upper Egypt

El-Faramawy¹,

El-Rashidy

Tawfik

et al. 2012

Hepat Mon

View full text Add to dashboard Cite

show abstract

“…In Jordan, HCV prevalence was 40.5% (13), whereas in Lebanon, 14% of patients were positive for HCV (25). In Saudi Arabia, a prevalence of 26% was reported in 2002 (30), while in 2011, 1.1% of multitransfused children had hepatitis B surface antigen, 3.5% were anti-HCVpositive, and none were anti-HIV-positive (31). The current and future burden of diseases caused by viral hepatitis in Egypt is significant.…”

Section: El-faramawy Aa M Et Al Tth: Where Do We Stand Now?mentioning

confidence: 99%

Transfusion Transmitted Hepatitis: Where Do We Stand Now? A One Center Study in Upper Egypt

El-Faramawy¹,

El-Rashidy

Tawfik

et al. 2012

Hepat Mon

View full text Add to dashboard Cite

As Egypt is a country of intermediate prevalence regarding HBV and of high prevalence regarding HCV infection, great effort should be made to prevent and control these infections .updating the knowledge about the prevalence of these infections particularly among the high risk groups is important to assess the efficacy of preventive measures and to highlight weak points in the strategy aiming to decrease the infection rate. This study is recommended to all clinicians involved in treatment of polytransfused patients for better outcome.Background: Despite progress made in the prevention of transfusion-transmitted infections (TTI) over the last few years, they continue to be a problem in many parts of the world, particularly in multitransfused patients. Objectives: The aim of this study was to estimate the prevalence of hepatitis B virus (HBV), hepatitis C virus (HCV), and to evaluate the screening and vaccination program among our cohort of multitransfused children from Qena, Upper Egypt. Patients and Methods: One-hundred children suffering from diseases requiring repeated blood transfusions were included in the study. They were classified into group 1, which included 67 children with thalassemia, and group 2, which included 33 children with hemophilia. Screening for hepatitis B surface antigen, hepatitis B surface antibody, hepatitis B core antibody and antibody to HCV was done using a second-generation enzyme-linked immunosorbent assay technique. Results: Only 12% of all patients were either acutely or chronically infected with HBV. 46% were immune due to previous vaccination, whereas 39% of patients were not protected from HBV infection. HCV antibodies were positive in 45% of cases. Seventy-eight patients had a complete hepatitis B vaccination in the form of three doses as documented by birth certificate. Thirty-six patients mentioned history suggestive of hepatitis. The prevalence of the studied hepatitis markers was similar in both the thalassemia and hemophilia groups of children. Conclusions: Transfusion-transmitted hepatitis is still a major problem for multitransfused children in Egypt. More effort is required to reduce the infection rate through proper screening of blood and blood products, strict emphasis on receiving the vaccine, regular follow-up for those children with a hepatitis B antibody titer, and providing booster doses for those in need.

show abstract

Seroprevalence of hepatitis B virus, hepatitis C virus, and human immunodeficiency virus infections in patients with hereditary hemoglobinopathies from Saudi

Cited by 2 publications

References 16 publications

Transfusion Transmitted Hepatitis: Where Do We Stand Now? A One Center Study in Upper Egypt

Transfusion Transmitted Hepatitis: Where Do We Stand Now? A One Center Study in Upper Egypt

Transfusion Transmitted Hepatitis: Where Do We Stand Now? A One Center Study in Upper Egypt

Contact Info

Product

Resources

About